New Review on PROSTVAC™ published by key Investigators from NCI
A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC™. This is the most comprehensive and updated Review on PROSTVAC™ so far.
Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, and Phase II trials have suggested a survival benefit after treatment withPROSTVAC™, especially in patients with indolent disease characteristics."
Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are very pleased that the scientific experts once again confirm their positive view on PROSTVAC™ and the potential use of the vaccine in earlier stages of the disease. We are looking forward to publish more data at a later stage."
PROSTVAC™ is a therapeutic vaccine moving into late stage clinical development that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC™ has the potential to extend survival with improved quality of life. PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement with Bavarian Nordic's U.S.-based subsidiary, BN ImmunoTherapeutics.
In clinical trials to date PROSTVAC™ and related PSA containing poxviral vaccines have been investigated in more than 500 patients for 10 years.